<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555539</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-012</org_study_id>
    <nct_id>NCT03555539</nct_id>
  </id_info>
  <brief_title>Study of Danicopan in Participants With Hepatic Impairment</brief_title>
  <official_title>A Phase 1, 2-Part, Open-Label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK)&#xD;
      of ACH-0144471 (danicopan) in participants with hepatic impairment (HI) as compared to&#xD;
      healthy matched participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">September 21, 2018</completion_date>
  <primary_completion_date type="Actual">September 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study was to be conducted sequentially in 2 parts.&#xD;
Part 1: Participants with moderate HI (based on Child-Pugh scores) were compared to demographically matched participants with normal hepatic function.&#xD;
Following a review of PK and safety data from Part 1, a decision was to be made by the principle investigators and the sponsor whether to conduct Part 2 of this study, which was planned to enroll participants with severe and mild HI.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under The Plasma Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) Of Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To Maximum Observed Plasma Concentration (Tmax) Of Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up visit (10 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Part 1: Healthy Match</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 200-milligram (mg) dose of danicopan on Day 1 in healthy participants (matched control group with normal hepatic function).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Moderate HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 200-mg dose of danicopan on Day 1 in participants with moderate HI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 1: Healthy Match</arm_group_label>
    <arm_group_label>Part 1: Moderate HI</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index range of 18.0 to 40.0 kilograms (kg)/square meter with a minimum body&#xD;
             weight of 50 kg at Screening.&#xD;
&#xD;
          -  Females must be of non-childbearing potential.&#xD;
&#xD;
          -  Males must agree to abstinence or use a highly effective method of contraception.&#xD;
&#xD;
        HI Participants:&#xD;
&#xD;
          -  Be sufficiently healthy for study participation.&#xD;
&#xD;
          -  Diagnosis of chronic (&gt;6 months) stable hepatic insufficiency.&#xD;
&#xD;
          -  A stable medication regimen.&#xD;
&#xD;
          -  In good general health at Screening and check-in, allowing for the concurrent&#xD;
             illnesses associated with HI.&#xD;
&#xD;
          -  Evidence of cirrhosis due to hepatitis C virus (HCV), hepatitis B virus (HBV)&#xD;
             infection, cryptogenic, alcohol abuse, or nonalcoholic steatohepatitis.&#xD;
&#xD;
          -  No evidence of hepatocellular carcinoma.&#xD;
&#xD;
          -  Have HI as assessed by a Child-Pugh classification score at Screening.&#xD;
&#xD;
        Healthy Participants:&#xD;
&#xD;
          -  Participants must be demographically matched to a hepatically impaired participant.&#xD;
&#xD;
          -  Medically healthy and without a clinically significant medical history.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of any other clinically significant deviation from normal in a clinical&#xD;
             laboratory for the match-controlled participants and laboratory findings beyond those&#xD;
             that are consistent with the degree of HI from hepatic participants.&#xD;
&#xD;
          -  History of any medical or psychiatric condition or disease.&#xD;
&#xD;
          -  Any previous procedure that could alter the absorption or excretion of orally&#xD;
             administered drugs.&#xD;
&#xD;
          -  Body temperature greater than or equal to 38 degrees centigrade on Day -1 or Day 1&#xD;
             prior to dosing; history of febrile illness or other evidence of infection within 14&#xD;
             days prior to dosing.&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse within 6 months prior to dosing; current&#xD;
             tobacco/nicotine user; positive for alcohol and/or drugs-of-abuse at Screening or&#xD;
             check in.&#xD;
&#xD;
          -  Participants who have received eculizumab at any dose or interval within the past 75&#xD;
             days.&#xD;
&#xD;
          -  Participation in any other investigational study drug trial 30 days before dosing.&#xD;
&#xD;
          -  Donation of whole blood from 3 months before dosing or of plasma from 30 days before&#xD;
             dosing; receipt of blood products within 6 months before dosing.&#xD;
&#xD;
        HI Participants:&#xD;
&#xD;
          -  Any acute or chronic non-hepatic condition that would limit the participant's ability&#xD;
             to participate in this study.&#xD;
&#xD;
          -  Any other unspecified reason that would make the participant unsuitable for&#xD;
             enrollment.&#xD;
&#xD;
          -  Any screening laboratory evaluation outside the laboratory reference ranges not&#xD;
             related to HI.&#xD;
&#xD;
          -  Fluctuating or rapidly deteriorating hepatic function within the screening period and&#xD;
             up to 30 days prior to Day 1.&#xD;
&#xD;
          -  History of chronic liver disease due to Wilson's disease.&#xD;
&#xD;
          -  History of liver or other solid organ transplants.&#xD;
&#xD;
        Healthy Participants:&#xD;
&#xD;
          -  Clinical laboratory evaluations outside of the reference range at Screening or&#xD;
             check-in.&#xD;
&#xD;
          -  Evidence of acute or chronic liver disease.&#xD;
&#xD;
          -  Use of any prescription medications/products within 14 days prior to dosing.&#xD;
&#xD;
          -  Use of over-the-counter, nonprescription preparations within 7 days prior to dosing.&#xD;
&#xD;
          -  Evidence of chronic HBV or chronic HCV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

